The landscape of COVID‐19 trials in Australia

  title={The landscape of COVID‐19 trials in Australia},
  author={Anna Lene Seidler and Mason Aberoumand and Jonathan Williams and Aidan L Tan and Kylie Elizabeth Hunter and Angela C Webster},
  journal={The Medical Journal of Australia},
  pages={58 - 61.e1}
The coronavirus disease 2019 (COVID-19) pandemic has seen a large number of clinical trials launched at unprecedented speed. We aimed to explore the landscape of COVID-19 trials in Australia, and to what extent Australian researchers have responded to global need for coordination and collaboration. We systematically searched the Australian New Zealand Clinical Trials Registry (ANZCTR) and from 1st January to 16th November 2020. We included all interventional… 

Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges

During the SARS-CoV-2 pandemic, astonishingly rapid research averted millions of deaths worldwide through new vaccines and repurposed and new drugs. Evidence use informed life-saving national

In the future simulations will replace clinical trials

In this very topical and timely debate Martin Ebert and Val Gebski debate whether in the future simulations will replace clinical trials.

The Complex Quest of Preventing Obesity in Early Childhood: Describing Challenges and Solutions Through Collaboration and Innovation

Some of the key challenges in early childhood obesity prevention are described and innovative and collaborative solutions to overcome these are outlined to accelerate the generation of high-quality evidence that can be implemented into policy and practice.



Clinical trials for the prevention and treatment of COVID‐19: current state of play

This paper summarises the 31 currently registered randomised trials with a target sample size of at least 1000 participants for COVID‐19, and grouped these trials into four categories: prophylaxis; treatment of outpatients with mild CO VID‐19;treatment of hospitalised patients with moderate COVID-19; and treatment of hospitalisation patients withmoderate or severe disease.

Core Outcomes Set for Trials in People With Coronavirus Disease 2019

Mortality, respiratory failure, multiple organ failure, shortness of breath, and recovery are critically important outcomes to be consistently reported in coronavirus disease 2019 trials.

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.

A prospective meta-analysis that pooled data from 7 randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19 found that low-dose dexamethasone reduced mortality in hospitalized patients with Cohen's disease who required respiratory support.

Changes in medical scientific publication associated with the COVID‐19 pandemic

The coronavirus disease 2019 (COVID19) pandemic has resulted in wideranging health, social and economic impacts and brought risk of misinformation, with consequent changes to medical practice and misdirection of scarce resources based on flawed evidence.

Improving Survival of Critical Care Patients With Coronavirus Disease 2019 in England: A National Cohort Study, March to June 2020*

There has been a substantial improvement in survival amongst people admitted to critical care with coronavirus disease 2019 in England, with markedly higher survival rates in people admitted in May and June compared with those admitted in March and April.

Data sharing—trialists' plans at registration, attitudes, barriers and facilitators: A cohort study and cross‐sectional survey

There is a gap between high in‐principle support for data sharing, and low in‐practice intention from investigators to share data from their own clinical trials, and multiple pathways exist to bridge this gap by addressing the identified barriers to data sharing.

Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors.

The challenges are substantial and the requisite mechanisms are not in place to mandate universal data sharing at this time, therefore, ICMJE will require the following as conditions of consideration for publication of a clinical trial report in the authors' member journals.

Pooling Data From Individual Clinical Trials in the COVID-19 Era.

This Viewpoint proposes principles and processes to allow pooling of individual patient data from clinical trials given decelerating participant recruitment at sites where the COVID-19 surge has been